Table 2 Key questions to inform an update of recommendations by the Task Force on prostate cancer screening in adults aged 18 years and older
Key questions | |
|---|---|
KQ1 | What are the benefits and harms of prostate cancer screening? a) Do the benefits and harms differ by screening modalities (i.e., PSA alone, DRE alone, or PSA+DRE)? b) In screening with PSA, do benefits and harms differ by PSA threshold value? c) Do the benefits and harms differ by age group (<55 years, 55–69 years, ≥70 years)? d) Do the benefits and harms differ by other risk factors such as race/ethnicity and/or family history? |
KQ2 | What are the benefits and harms of incorporating additional information (e.g., risk stratification, MRI) into clinical decision making following an elevated PSA test? |
KQ3 | What are the benefits and harms of treatment strategies for screen-detected prostate cancer? |
KQ4 | What are patients’ values and preferences for screening for prostate cancer? |